3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
6
Lenalidomide
3
Bendamustine Hydrochloride
3
pirtobrutinib
2
Cyclophosphamide
2
venetoclax
1
umbralisib
1
ublituximab
1
tocilizumab
1
obinutuzumab
1
idelalisib
1
glofitamab
1
fludarabine
1
atezolizumab
1
acalabrutinib
1
Vincristine
1
Standard of Care
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Non-Hodgkin
×
umbralisib
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA